Management of hematological toxicities after BCMA-directed CAR-T cell therapy

Blood Cancer Journal 2026 Open access

Read full text
Authors: Joselle Cook, Supriya Gupta, Nadine Abdallah, Matthew J. Rees, Claire Graham, Lay She Ng, Radhika Bansal, Andre De Menezes Silva Corraes, Kristina Helms, Rahma Warsame, David Dingli, Wilson Gonsalves
+17 more Taxiarchis Kourelis, Morie Gertz, Suzanne Hayman, Nelson Leung, Prashant Kapoor, L. Y. hwa, A C Fonder, Miriam Hobbs, L Bergsagel, Udit Yadav, Erin E. Wiedmeier-Nutor, Saurabh Chhabra, Rafael Fonseca, Sikander Ailawadhi, Ricardo Parrondo, Shaji Kumar, Yi Lin
DOI: 10.1038/s41408-026-01455-5
Cited by: 4
References: 25

Abstract

The CAR-HEMATOTOX (CAR-HT) score can assess hematotoxicity risk, but its utility in guiding supportive care remains underexplored. We analyzed 224 multiple myeloma patients treated with BCMA-directed CAR-T therapy (2016-2024), stratified by CAR-HT score (low

Fields of Study & Subjects

CAR-T cell therapy research Multiple Myeloma Research and Treatments Immunotherapy and Immune Responses

Publication details

Journal / source
Blood Cancer Journal
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Publication date
30 March 2026
Language
EN